Skip to main content
Premium Trial:

Request an Annual Quote

Anthony Salerno, Brian Osborne, Ann Loraine

Premium
GenomeQuest has hired Anthony Salerno as vice president of strategic business development. In this role, Salerno will be responsible for creating and maintaining alliances with the next generation sequencing vendor community, GenomeQuest said.
 
Salerno joins the company from Agilent Technologies, where he served as director of strategic business development. Prior to Agilent, he was founder, president, and CEO of VectorObjects; managing director of BioDynamics Associates; senior consultant at Vysis, now part of Abbott Diagnostics; and founding vice president of sales and marketing at Tropix, now a division of Applied Biosystems.
 

 
Brian Osborne has joined bioinformatics consulting firm the BioTeam as principal investigator. In this role, he will work with the company’s clients in the area of high-performance computing, informatics, and next-generation sequencing.
 
Prior to joining the BioTeam, Osborne had his own consulting company, ZBIO. Before that, he was chief technology officer and director of informatics at Cognia and director of IT at OSI Pharmaceuticals. He also served as group leader for bioinformatics at Cadus Pharmaceuticals and worked in the plant genome sequencing lab at the University of California, Berkeley.
 

 
Ann Loraine has joined the staff of the Charlotte Research Institute and Bioinformatics Research Center at the University of North Carolina, Charlotte, as associate professor of bioinformatics. Loraine is the first research faculty member to join the North Carolina Research Campus, a $1.5 billion project being developed by billionaire Dole Food owner David Murdock. She is the first of six UNC Charlotte researchers expected on the campus this year, UNC Charlotte said.
 
Loraine was most recently an assistant adjunct professor in the department of computer and information sciences at the University of Alabama at Birmingham. Prior to that, she was a bioinformatics scientist at Affymetrix and Neomorphic.

Filed under

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.